Flow cytometric analysis of melanoma cells, double-stained with Ipilimumab and an anti-CD56 (NCAM) Ab, showed that the cell lines expressed CTLA-4 and CD56 simultaneously (representative profiles are shown in Figure 2A), although at variable intensity (Table 1). Here, NCAM1 is linked to melanoma.